Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin

Cancer Research

Volumn 59, Issue 9, 1999, Pages 2102-2106

  Moreland, Nicole J ^a   Illand, Maureen ^a   Kim, Young Tae ^a   Paul, Jim ^b   Brown, Robert ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APHIDICOLIN; CARBOPLATIN; DNA POLYMERASE; METHYLNITROSOUREA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SURVIVAL; DNA REPAIR; DNA REPLICATION; DRUG MECHANISM; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APHIDICOLIN; APOPTOSIS; BASE PAIR MISMATCH; CARRIER PROTEINS; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA, NEOPLASM; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; G2 PHASE; HUMANS; METHYLNITROSOUREA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033136042     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rosenberg, B. Fundamental studies with cisplatin. Cancer (Phila.), 5: 2303-2316, 1985.
2. Zamble, D. B., and Lippard, S. J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci., 20: 435-439, 1995.
3. Fichtinger-Schepman, A. M., van der Veer, J. L., Den Hartog, J. H., Lohman, P. H. M., and Reedijk, J. Adducts of the antitumour drug cis-diamminedichloroplatinum II with DNA: formation, identification and quantification. Biochemistry, 24: 707-713, 1985.
4. Kaye, S. B. Ovarian cancer, from the laboratory to the clinic: challenges for the future. Ann. Oncol., 7: 9-13, 1996.
5. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (Cold Spring Harbor), 2: 35-43, 1990.
6. Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R. M., and Brown, R. Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56: 1374-1381, 1996.
7. Fink, D., Aebi, S., and Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 4: 1-6, 1998.
8. Drummond, J. T., Anthoney, A., Brown, R., and Modrich, P. Cisplatin and Adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem., 271: 19645-19648, 1996.
9. Durant, S., Morris, M., Illand, M., McCormick, C., Hirst, G. L., Borts, R. H., and Brown, R. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr. Biol., 9: 51-54, 1999.
10. Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., and Chaney, S. G. The role of hmlh1, hmsh3, and hmsh6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res., 58: 3579-3585, 1998.
11. Karran, P., and Hampson, R. Genomic instability and tolerance to alkylating agents. Cancer Surv., 28: 69-85, 1996.
12. Hoffmann, J., Pillaire, M., Lesca, C., Burnouf, D., Fuchs, R. P., Defais, M., and Villani, G. Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates. Proc. Natl. Acad. Sci. USA, 93: 13766-13769, 1996.
13. Hoffmann, J., Locker, D., Villani, G., and Leng, M. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts. J. Mol. Biol., 270: 539-543, 1997.
14. Wood, R. D., and Shivji, M. K. K. Which DNA polymerases are used for DNA repair in eukaryotes? Carcinogenesis (Lond.), 18: 605-610, 1997.
15. Masuda, H., Tanaka, T., Matsuda, H., and Kusaba, I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res., 50: 1863-1866, 1990.
16. O'Dwyer, P. J., Moyer, J. D., Suffness, M., Harrison, S. D., Cysyk, R., Hamilton, T. C., and Plowman, J. Antitumor activity and biochemical effects of aphidocolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res., 54: 724-729, 1994.
17. Sargent, J. M., Elgie, A. W., Williamson, C. J., and Taylor, C. G. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Br. J. Cancer, 74: 1730-1733, 1996.
18. Dempke, W. C. M., Shellard, S. A., Fichtinger-Schepman, A. M. J., and Hill, B. T. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian cell lines in vitro. Carcinogenesis (Lond.), 12: 525-528, 1991.
19. Damia, G., Tagliabue, G., Zucchetti, M., Davoli, E., Sessa, C., Cavalli, F., and D'Incalci, M. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother. Pharmacol., 30: 459-464, 1992.
20. Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., and Anthoney, D. A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15: 45-52, 1997.
21. Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. B. Increased accumulation of p53 in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55: 678-684, 1993.
22. Ji, C., Marnett, L. J., and Pietenpol, J. A. Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels. Oncogene, 15: 2749-2753, 1997.
23. Dolan, M. E., Stine, L., Mitchell, R. B., Moschel, R. C., and Pegg, A. E. Modulation of mammalian O-6-alkylguanine-DNA alkyltransferase in vivo by O-6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Comm., 2: 371-377, 1990.
24. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor), 2: 275-280, 1990.
25. Mamenta, E. L., Poma, E. E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L., and Chancy, S. G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500-3505, 1994.
26. 2 cell cycle checkpoint. Cancer Res., 55: 3721-3725, 1995.
27. 2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res., 58: 767-778, 1998.
28. Fujita, M., Enomoto, T., Yoshino, K., Nomura, T., Buzard. G. S., and Inoue, M. Microsatellite instability and alterations in trie hMSH2 gene in human ovarian cancer. Int. J. Cancer, 64: 361-366, 1995.
29. King, B. L., Carcangiu, M. L., Carter, D., Kiechle, M., Pfisterer, J., Pfleiderer, A., and Kacinski, B. M. Microsatellile instability in ovarian neoplasms. Br. J. Cancer, 72: 376-382, 1995.
30. Sessa, C., Zucchetti, M., Davolli, E., Califano, R., Cavalli, F., Frustaci, S., Gumbrell, A. S., Winograd, B., and D'Incalci, M. Phase 1 and clinical pharmacological evaluation of aphidicolin glycinate. J. Natl. Cancer Inst., 83: 1160-1164, 1991.